Comparison of prognosis and pathological response between FGFR3-mutated and FGFR3-wildtype patients in IMvigor210 cohort after PSM. Data were analyzed by χ2 test
| Variables | FGFR3-mutated (n=39) | FGFR3-wildtype (n=39) | P value |
| Median OS (months), median (IQR) | 9.2 (5.9–NE) | 21.0 (13.3–NE) | 0.015 |
| OS at 6 months, (%) | 62.0 | 89.7 | |
| OS at 1 year, (%) | 33.8 | 74.1 | |
| Tumor response, n (%) | 0.136 | ||
| CR | 1 (2.6) | 2 (5.1) | |
| PR | 9 (23.0) | 12 (30.8) | |
| SD | 6 (15.4) | 12 (30.8) | |
| PD | 23 (59.0) | 13 (33.3) | |
| Disease control rate (CR+PR+SD), n (%) | 16 (41.0) | 26 (66.7) | 0.023 |
CR, complete response; FGFR3, fibroblast growth factor receptor 3 ; NE, not estimable; OS, overall survival; PD, progressive disease; PR, partial response; PSM, propensity score matched; SD, stable disease.